Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Rüdiger Hehlmann, MD, PhD, Heidelberg University, Heidelberg, Germany, gives a presentation on advances in treatments for chronic myeloid leukemia (CML), managing CML in the third-line setting, and tyrosine kinase discontinuation (TKI) at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.